Glucagon-Like Peptide 1 Receptor Agonists (GLP1RA) and Sodium-glucose co-transporter-2 inhibitors (SGLT2i): Making a pragmatic choice in diabetes management

Authors

  • Sanjay Kalra Department of Endocrinology, Bharti Hospital, Karnal, India
  • Saptarshi Bhattacharya Department of Endocrinology, Max Hospital, Patparganj, New Delhi, India
  • Nitin Kapoor 3Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, India, and Non communicable disease unit, The Nossal Institute for Global Health, Melbourne School of Population and global health, University of Melbourne, Victoria, Australia.

DOI:

https://doi.org/10.47391/JPMA.22-64

Abstract

created opportunities for comprehensive diabetes care. Two classes of drugs, GLP1RA (glucagon-like peptide 1 receptor agonists), and SGLT2i (sodium glucose cotransporter 2 inhibitors) have demonstrated their efficacy in glucose control as well as cardiovascular risk reduction. While both can be used together, there is an ongoing debate regarding their relative advantages and limitations. We present a clinical perspective to compare and control these two classes of drugs, and promote rational prescription in diabetes praxis.

Keywords: Canagliflozin, CV risk reduction, dapagliflozin, dulaglutide, empagliflozin, GLP1RA, liraglutide, obesity, semaglutide, SGLT2i.

Downloads

Published

2022-05-11

Issue

Vol. 72 No. 5 (2022): MAY

Section

PRIMARY CARE DIABETES

Most read articles by the same author(s)

1 2 3 4 > >>